The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics
Open accessAbstract
The repositioning or ‘repurposing’ of existing therapies for alternative disease indications is an attractive approach that can save significant investments of time and money during drug development. For cancer indications, the primary goal of repurposed therapies is on efficacy, with less restrictions on safety due to the immediate need to treat this patient population. This report provides a high-level overview of how drug developers pursuing repurposed assets have previously navigated funding efforts, regulatory affairs, and intellectual property laws to commercialize these ‘new’ medicines in oncology. This article provides insight into funding programs (e.g. government grants, philanthropic organizations) that academic and corporate initiatives can leverage to repurpose drugs for cancer. In addition, we highlight previous examples where secondary uses of existing, FDA- or EMA-approved therapies have been predicted in silico and successfully validated in vitro and/or in vivo (i.e. animal models and human clinical trials) for certain oncology indications. Lastly, we describe the strategies that the pharmaceutical industry has previously employed to navigate regulatory considerations and successfully commercialize their drug products. These factors must be carefully considered when repurposing existing drugs for cancer to best benefit patients and drug developers alike.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207
Chong, C. R., & Sullivan, D. J. (2007) · Nature · doi:10.1038/448645a · Cited by 983
Desta, Z., Ward, B. A., Soukhova, N. V., & Flockhart, D. A. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.065607 · Cited by 645
A survey of current trends in computational drug repositioning
Li, J., Zheng, S., Chen, B., Butte, A. J., Swamidass, S. J., & Lu, Z. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbv020 · Cited by 555
Drug repurposing from an academic perspective
Oprea, T. I., Bauman, J. E., Bologa, C. G., Buranda, T., Chigaev, A., Edwards, B. S., Jarvik, J. W., Gresham, H. D., Haynes, M. K., Hjelle, B., et al. (2011) · Drug Discovery Today: Therapeutic Strategies · doi:10.1016/j.ddstr.2011.10.002 · Cited by 364
Metformin in cancer prevention and therapy.
Kasznicki, J., Śliwińska, A., & Drzewoski, J. (2014) · PubMed · doi:10.3978/j.issn.2305-5839.2014.06.01 · Cited by 316
Drug repurposing in oncology—patient and health systems opportunities
Bertolini, F., Sukhatme, V. P., & Bouche, G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.169 · Cited by 294
Applications of Connectivity Map in drug discovery and development
Qu, X. A., & Rajpal, D. K. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.017 · Cited by 235
Trifluoperazine for schizophrenia
Marques, L. D. O., Soares, B., & Silva de Lima, M. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003545.pub2 · Cited by 228
Yeh, C.-T., Wu, A. T. H., Chang, P. M.-H., Chen, K.-Y., Yang, C.-N., Yang, S.-C., Ho, C.-C., Chen, C.-C., Kuo, Y.-L., Lee, P.-Y., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201207-1180oc · Cited by 206
Chohan, T., Qian, H., Pan, Y., & Chen, J.-Z. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106113633 · Cited by 185
Grunberg, S. M., Weiss, M. H., Russell, C. A., Spitz, I. M., Ahmadi, J., Sadun, A., & Sitruk-Ware, R. (2006) · Cancer Investigation · doi:10.1080/07357900601062339 · Cited by 183
(2016) · ecancermedicalscience · doi:10.3332/ecancer.2014.442 · Cited by 173
Computational and Practical Aspects of Drug Repositioning
Oprea, T. I., & Overington, J. P. (2015) · Assay and Drug Development Technologies · doi:10.1089/adt.2015.29011.tiodrrr · Cited by 119
Yildirim, O., Gottwald, M., Schüler, P., & Michel, M. C. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00461 · Cited by 108
Kim, S. J., Nakayama, S., Miyoshi, Y., Taguchi, T., Tamaki, Y., Matsushima, T., Torikoshi, Y., Tanaka, S., Yoshida, T., Ishihara, H., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm358 · Cited by 101
Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma
Satoh, K., Zhang, L., Zhang, Y., Chelluri, R. R., Boufraqech, M., Nilubol, N., Patel, D., Shen, M., & Kebebew, E. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2256 · Cited by 101
Repurposing Drugs in Oncology: Next Steps
Verbaanderd, C., Meheus, L., Huys, I., & Pantziarka, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.06.007 · Cited by 85
Shi, X., Li, H., Yao, H., Liu, X., Li, L., Leung, K., Kung, H., Lu, D., Wong, M., & Lin, M. C. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132072 · Cited by 83
Chen, M., Yang, W.-L. R., Lin, K., Liu, C.-H., Liu, Y.-W., Huang, K., Chang, P. M., Lai, J.-M., Hsu, C.-N., Chao, K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027186 · Cited by 76
DeSigN: connecting gene expression with therapeutics for drug repurposing and development
Lee, B. K. B., Tiong, K. H., Chang, J. K., Liew, C. S., Rahman, Z. A. A., Tan, A. C., Khang, T. F., & Cheong, S. C. (2017) · BMC Genomics · doi:10.1186/s12864-016-3260-7 · Cited by 73
Repositioned drugs: integrating intellectual property and regulatory strategies
Smith, R. B. (2011) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.06.008 · Cited by 64
Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinoma
Shi, X., Li, H., Yao, H., Liu, X., Li, L., Leung, K., Kung, H., & Lin, M. C. M. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4310 · Cited by 60
In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma
Pessetto, Z. Y., Chen, B., Alturkmani, H. J., Hyter, S. D., Flynn, C. A., Baltezor, M. J., Ma, Y., Rosenthal, H. G., Neville, K. A., Weir, S. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13385 · Cited by 60
CDK1 and CDK2 activity is a strong predictor of renal cell carcinoma recurrence
Hongo, F., Takaha, N., Oishi, M., Ueda, T., Nakamura, T., Naitoh, Y., Naya, Y., Kamoi, K., Okihara, K., Matsushima, T., et al. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.05.006 · Cited by 51
Affordable orphan drugs: a role for not‐for‐profit organizations
Davies, E. H., Fulton, E., Brook, D., & Hughes, D. A. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13240 · Cited by 48
Huang, L., Zhao, S., Frasor, J. M., & Dai, Y. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022274 · Cited by 43
Scientific advice — is drug repurposing missing a trick?
Pantziarka, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.69 · Cited by 37
Identification of repurposed small molecule drugs for chordoma therapy
Xia, M., Huang, R., Sakamuru, S., Alcorta, D. A., Cho, M.-H., Lee, D., Park, D. M., Kelley, M. J., Sommer, J., & Austin, C. P. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.24596 · Cited by 36
Cancer Drugs: An International Comparison of Postlicensing Price Inflation
Savage, P. M., Mahmoud, S., Patel, Y. B., & Kantarjian, H. M. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2016.014431 · Cited by 36
Insurance companies' perspectives on the orphan drug pipeline.
Handfield, R., & Feldstein, J. (2013) · PubMed Central · Cited by 24
From NPC Therapeutic Target Identification to Potential Treatment Strategy
Lan, M., Chen, C., Lin, K., Lee, S., Yang, W.-L. R., Hsu, C.-N., Wu, J., Ho, C., Lin, J., & Huang, C. F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0966 · Cited by 19
In silico identification of potential targets and drugs for non‐small cell lung cancer
Huang, C., Wu, M., Chang, P. M., Huang, C. F., & Ng, K. (2014) · IET Systems Biology · doi:10.1049/iet-syb.2013.0035 · Cited by 15
Using computational strategies to predict potential drugs for nasopharyngeal carcinoma
Lan, M., Yang, W.-L. R., Lin, K., Lin, J., Shann, Y., Ho, C., & Huang, C. F. (2013) · Head & Neck · doi:10.1002/hed.23464 · Cited by 14
Ke, K., Li, H., Yao, H., Shi, X., Dong, C., Zhu, Y., Liu, X., Li, L., Leung, K., Wong, M., et al. (2016) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12872 · Cited by 12
Trifluoperazine for schizophrenia
Marques, L., Lima, M., & Soares, B. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003545 · Cited by 6
Cited by
Artificial intelligence in drug development: Present status and future prospects
Mak, K.-K., & Pichika, M. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.014 · Cited by 1,018
Drug repurposing: a promising tool to accelerate the drug discovery process
Parvathaneni, V., Kulkarni, N. S., Muth, A., & Gupta, V. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.014 · Cited by 597
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Drug repurposing for antimicrobial discovery
Farha, M. A., & Brown, E. D. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0357-1 · Cited by 360
Machine learning identifies candidates for drug repurposing in Alzheimer’s disease
Rodriguez, S., Hug, C., Todorov, P., Moret, N., Boswell, S. A., Evans, K., Zhou, G., Johnson, N. T., Hyman, B. T., Sorger, P. K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21330-0 · Cited by 299
Metadata
- Authors
- Hernandez, J. J., Pryszlak, M., Smith, L., Yanchus, C., Kurji, N., Shahani, V. M., & Molinski, S. V.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2017-11-14
- Volume
- 7
- Pages
- 273-273
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2770849724
- Cited by
- 281
- References
- 39
- FWCI
- 45.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.